首页|沙库巴曲缬沙坦联合美托洛尔治疗慢性心力衰竭患者的效果

沙库巴曲缬沙坦联合美托洛尔治疗慢性心力衰竭患者的效果

扫码查看
目的:研究沙库巴曲缬沙坦联合美托洛尔治疗慢性心力衰竭(CHF)患者的效果。方法:选取 2022 年 1 月—2023 年 9 月重庆市万盛经济技术开发区中医院收治的 94 例CHF患者。根据随机数表法将其分为研究组和对照组,各 47 例。对照组给予美托洛尔,研究组给予美托洛尔联合沙库巴曲缬沙坦。比较两组治疗前后血清学指标、心功能指标、炎症因子、血管内皮功能指标及不良反应。结果:治疗后,研究组氨基末端脑钠肽前体(NT-proBNP)、细胞间黏附分子-1(ICAM-1)、血管紧张素Ⅱ(AngⅡ)、生长分化因子 15(GDF-15)、可溶性生长刺激表达基因 2 蛋白(sST2)、人亲环蛋白(CypA)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)水平均低于对照组,差异有统计学意义(P<0。05)。治疗后,研究组左室短轴缩短率(LVFS)、左室射血分数(LVEF)、每博输出量(SV)、一氧化氮(NO)、降钙素基因相关肽(CGRP)及一氧化氮合酶(NOS)均高于对照组,差异有统计学意义(P<0。05)。两组不良反应发生率比较,差异无统计学意义(P>0。05)。结论:沙库巴曲缬沙坦联合美托洛尔能有效改善CHF患者血清学指标、心功能、血管内皮功能,降低炎症因子水平。
Effect of Sacubitril and Valsartan Combined with Metoprolol in the Treatment of Patients with Chronic Heart Failure
Objective:To study the effect of Sacubitril and Valsartan combined with Metoprolol in the treatment of patients with chronic heart failure(CHF).Method:A total of 94 CHF patients admitted to the Chongqing Wansheng Economic and Technological Development Zone Traditional Chinese Medicine Hospital from January 2022 to September 2023 were selected.According to random number table method,the patients were divided into study group and control group,47 cases in each group.The control group was given Metoprolol,and the study group was given Metoprolol combined with Sacubitril and Valsartan.The serological indexes,cardiac function indexes,inflammatory factors,vascular endothelial function indexes before and after treatment and adverse reactions were compared between the two groups.Result:After treatment,the amino terminal brain natriuretic peptide precursor(NT-proBNP),intercellular adhesion molecule-1(ICAM-1),angiotensin Ⅱ(AngⅡ),growth differentiation factor 15(GDF-15),soluble growth stimulation expression gene 2 protein(sST2),human cyclophilin(CypA),interleukin-6(IL-6),high sensitive C-reactive protein(hs-CRP)and procalcitonin(PCT)levels in the study were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the left ventricular short axis shortening rate(LVFS),left ventricular ejection fraction(LVEF),output per bo(SV),nitric oxide(NO),calcitonin gene-related peptide(CGRP)and nitric oxide synthase(NOS)in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Sacubitril and Valsartan combined with Metoprolol can effectively improve the serological indexes,cardiac function and vascular endothelial function of CHF patients,and reduce the level of inflammatory factors.

Chronic heart failureSacubitril and valsartanMetoprololCardiac function

刘洪波

展开 >

重庆市万盛经济技术开发区中医院 重庆 400800

慢性心力衰竭 沙库巴曲缬沙坦 美托洛尔 心功能

2024

中外医学研究
中国医院管理杂志社

中外医学研究

影响因子:1.149
ISSN:1674-6805
年,卷(期):2024.22(18)